Key Metrics
6.2
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.005 - 0.01
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
94
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.91
5-Year SI
5-year SI
- N/A 2-year SI
- 0.9 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q2 Oncology
- Q1 Pharmacology
- Q1 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.85
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
2 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
71%
4 to 6 months
27%
7 to 9 months
3%
Above 9 months
0%
Did you find this useful?
Thank you for your feedback.
Topics Covered
- Drug discovery
- Cancer
- Lung cancer
- Maximum tolerated dose
- Whole blood
- Bioinformatics analysis
- Hepatocellular carcinoma
- Toxicity
- Signal transduction
- Breast cancer
- Immunotherapy
- Oral administration
- Epidermal growth factor receptor
- Nivolumab
- Chemoradiotherapy
- Overall survival
- Erlotinib
- Microscale thermophoresis
- Mesothelioma
- Progression-free survival
Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Investigational New Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.
- 6 Nov 24
- Investigational new drugs
-
Full paper
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.
- 4 Nov 24
- Investigational new drugs
-
Full paper
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
- 26 Oct 24
- Investigational new drugs
-
Full paper
Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review.
- 21 Oct 24
- Investigational new drugs
-
Full paper
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models.
- 21 Oct 24
- Investigational new drugs
-
Full paper
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
- 10 Oct 24
- Investigational new drugs
Scite analysis
Powered by scite_
3.8k articles received 56.8k citations see all
- 2,167 Supporting
- 53,718 Mentioning
- 236 Contrasting
Editorial notices
- 1 Retractions
- 0 Withdrawals
- 39 Corrections
- 60 Errata
- 0 Expression of Concern
FAQs
How long has Investigational New Drugs been actively publishing?
Investigational New Drugs has been in operation since 1983 till date.
What is the publishing frequency of Investigational New Drugs ?
Investigational New Drugs published with a Bi-monthly frequency.
How many articles did Investigational New Drugs publish last years ?
In 2023, Investigational New Drugs published 91 articles.
What is the eISSN & pISSN for Investigational New Drugs ?
For Investigational New Drugs,eISSN is 1573-0646 and pISSN is0167-6997.
What is Citescore for Investigational New Drugs ?
Citescore for Investigational New Drugs is 6.2.
What is H index for Investigational New Drugs ?
H index for Investigational New Drugs is 94.
What is SNIP score for Investigational New Drugs ?
SNIP score for Investigational New Drugs is 0.85.
What is the SJR for Investigational New Drugs ?
SJR for Investigational New Drugs is Q1.
Who is the publisher of Investigational New Drugs ?
SPRINGER is the publisher of Investigational New Drugs.